Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
P78317
UPID:
RNF4_HUMAN
Alternative names:
RING finger protein 4; Small nuclear ring finger protein
Alternative UPACC:
P78317; B2R6D6; D6RF58; Q49AR8
Background:
E3 ubiquitin-protein ligase RNF4, also known as RING finger protein 4, plays a pivotal role in cellular processes by mediating polyubiquitination and targeting proteins for proteasomal degradation. It is involved in crucial cellular responses such as chromosome alignment, spindle assembly, and the regulation of transcription, enhancing both basal and steroid receptor-mediated transcriptional activation.
Therapeutic significance:
Understanding the role of E3 ubiquitin-protein ligase RNF4 could open doors to potential therapeutic strategies.